BioArctic AB (publ)
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- BioArctic AB (publ) is a Swedish research-based biopharmaceutical company specializing in disease-modifying treatments and diagnostics for neurodegenerative diseases. The company’s core products and services include the development of biological drugs such as therapeutic monoclonal antibodies targeting Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and complete spinal cord injury. Key product candidates in its pipeline include lecanemab (BAN2401), which is in phase 3 clinical trials and developed in collaboration with Eisai for Alzheimer's disease, as well as additional antibodies such as exidavnemab and pyroglutamate-amyloid-beta (BAN1503 and BAN2803), which leverage the company's proprietary BrainTransporter™ technology designed to enhance drug delivery across the blood-brain barrier. BioArctic also focuses on diagnostic biomarkers and combined drug-device treatments for central nervous system (CNS) disorders. The company operates primarily in the Nordic region and globally through partnerships, notably with Eisai and Bristol Myers Squibb. Recent major changes include a global exclusive license agreement signed with Bristol Myers Squibb in late 2024 for its PyroGlutamate-amyloid-beta antibody program, including BAN1503 and BAN2803, which generated an upfront payment of USD 100 million for BioArctic along with the potential for up to USD 1.25 billion in development, regulatory, and commercial milestones, plus tiered royalties on global sales. BioArctic retains co-commercialization rights in the Nordic region. Additionally, BioArctic has prepared for joint commercialization with Eisai of lecanemab (marketed as Leqembi®) in the Nordic region, with Eisai responsible for global development, regulatory approvals, and commercialization. Leqembi, derived from pioneering research by Professor Lars Lannfelt, has demonstrated potential to delay Alzheimer's disease progression significantly. BioArctic continues to expand its research portfolio, emphasizing innovation with ongoing clinical trials and collaborations focused on unmet medical needs in CNS diseases. Founded in 2003 and headquartered in Stockholm, Sweden, BioArctic AB publicly trades on Nasdaq Stockholm Large Cap (ticker: BIOA B). The company also includes the subsidiary SpineMedical AB and emphasizes strategic partnerships with global pharmaceutical firms to advance treatment development and commercialization. Its business segments comprise drug discovery, clinical development, licensing, and commercial rights management for CNS-focused therapeutics and diagnostics, with a geographic footprint extending through Nordic markets and global collaborations. BioArctic’s vision is centered on creating innovative treatments for severe brain diseases, supported by a robust pipeline of antibody therapies and proprietary delivery technologies. The company continuously advances clinical programs across Alzheimer’s disease, Parkinson’s disease, ALS, and spinal cord injuries while leveraging strategic alliances to enhance market reach and therapeutic impact. This comprehensive approach situates BioArctic as a leading innovator in the neurodegenerative disease biopharma sector with a strong focus on both research and commercialization initiatives addressing critical patient needs worldwide. This description reflects information current as of late 2025 based on publicly available sources and company disclosures.
Company News
Number of shares and votes in BioArctic AB (publ) as of August 31, 2026
BioArctic AB (publ) (BRCTF) Q2 2026 Earnings Call Transcript
BioArctic and Mesenkia enter oncology research collaboration
Invitation to presentation of BioArctic's second quarter report for April - June 2026 on August 26 at 9:30 a.m. CEST
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technology
Number of shares and votes in BioArctic AB (publ) as of May 29, 2026
Bulletin from the Annual General Meeting in BioArctic AB (publ)
BioArctic AB (publ) (BRCTF) Q1 2026 Earnings Call Transcript
BioArctic Interim Report for the period January - March 2026
Invitation to presentation of BioArctic's first quarter report for January - March 2026 on May 20 at 9:30 a.m. CET
Number of shares and votes in BioArctic AB (publ) as of February 27, 2026
BioArctic AB (publ) (BRCTF) Q4 2025 Earnings Call Transcript
BioArctic Interim Report for the period October - December 2025
Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET
Leqembi included in China's commercial insurance innovative drug list
New data on lecanemab to be presented at CTAD conference
Leqembi® approved for IV maintenance treatment in the United Kingdom
BioArctic AB (publ) (BRCTF) Q3 2025 Earnings Call Transcript
Interim Report for the period July - September 2025: BioArctic